The Plateau as Physical Necessity: Why the Weight-Loss Trajectory Under Long-Term GLP-1 Receptor Agonism Does Not Require an Energy-Gap Explanation

1. The Clinical Fact and the Proposed Mechanism

Hubert et al. document a clear pattern: during prolonged tirzepatide treatment, weight loss is initially rapid, then progressively slows, and eventually plateaus [1]. Their description of the trajectory is useful. Their causal account is not.

They attribute the plateau to a narrowing energy gap. This interpretation rests on two structural features of the modeling framework that undermine the causal claim.

2. Fixed Energy Density Collapses Distinct Tissues

The analysis converts all weight change into energy units using a constant of 7170 kcal/kg [1]. This is a statistical average, not a physical constant. Fat, lean tissue, glycogen and associated water differ substantially in energy density. Lean-mass loss frequently accounts for 20–40% of total weight reduction under GLP-1 receptor agonist therapy [2,3]. Equating one kilogram of lean tissue with one kilogram of adipose tissue introduces systematic error into every derived energy-deficit estimate.

3. The Convergence Is True by Construction

The authors report that energy intake rose and eventually equaled energy expenditure [1]. Their methods section states that intake was estimated by balancing modeled expenditure against the caloric equivalent of observed weight change. Intake is therefore the residual required to make the equations balance. As weight change tends to zero, the residual must tend to zero.

The model does not observe a narrowing energy gap. It re-encounters the constraint built into its estimation procedure. A causal claim cannot be grounded in a relationship that is true by definition.

4. The Trajectory Is Required by Mass-Dependent Outflow

Regard the human body as a mass reservoir. Net mass outflow – the excretion of oxidation products – depends on the quantity of mass retained. When outflow rate scales with retained mass, the integrated trajectory of mass loss is necessarily decelerating: rapid at first, progressively slower, and asymptotic to a new steady state. This is Torricelli’s law applied to biological mass clearance [4].

Torricelli’s law itself is not in dispute. It is a direct consequence of mass conservation and Bernoulli’s principle. The present argument does not claim to have discovered a new biological law. It claims something more limited and more rigorous: once the body is treated as a mass reservoir whose net outflow depends on the mass still retained, the decelerating trajectory follows by mathematical necessity.

One may refine the quantitative details of human mass clearance, but the core premises – that the body is a mass reservoir and that net outflow depends on retained mass – are physically well-grounded. Once they are granted, the decelerating trajectory is required by the structure of the system. The same logic applies to an ordinary draining tank: we do not need experiments to know that the outflow slows as the level falls. The result is geometric, not optional.

This distinction – between an empirical regularity and a geometric necessity – is often blurred in biomedical discussion. Yet it is decisive. If the plateau is a necessary consequence of mass-dependent outflow, then invoking additional adaptive mechanisms to explain the same trajectory is redundant.

Figure 1 makes the contrast explicit. Panel A shows the conventional reading: the decelerating curve is attributed to a narrowing energy gap derived from the model itself. Panel B shows the mass-balance reading: the identical curve is the expected geometric consequence of mass-dependent outflow. The inset schematic of a draining reservoir renders the physical analogy concrete.

The qualitative match with the trajectory reported by Hubert et al. is exact [1]. The same decelerating pattern appears under caloric restriction and after bariatric surgery. One physical relationship accounts for all three.

If the plateau expresses mass-dependent outflow, the “narrowing energy gap” is not an independent cause. It is the same phenomenon restated in energetic units.

5. Post-Treatment Regain as Mass Restoration

After treatment cessation, intake rose above baseline and partial weight regain occurred [1]. The standard interpretation invokes appetite rebound. A more direct reading is that the system regulates mass. Once pharmacologic suppression is removed, intake increases to restore previously lost mass, including lean tissue. This is mass restoration, not energy compensation.

6. Clinical Implication

If the plateau is regarded as biologic resistance, the rational response is escalation – higher doses, additional agents, or intensified behavioral pressure. If the plateau is the expected behavior of a mass reservoir approaching equilibrium, the rational response is different: preserve lean mass, support function, and optimize health at the new mass.

In the era of highly effective incretin therapies, mistaking a geometric necessity for treatment failure risks unnecessary escalation and misdirected clinical effort. The plateau is not a signal that the drug is “losing efficacy.” It is information about the physical structure of the system being treated.

7. Conclusion

The weight-loss plateau under long-term tirzepatide is real. The claim that it is caused by a narrowing energy gap is not supported by independent measurement of intake and is, within the modeling framework used, true by definition. The same trajectory is the necessary consequence of mass outflow that depends on retained mass.

Energy accounting remains a convenient approximation. It is not the most precise description of why weight loss decelerates and plateaus.